A phase I, randomized, double-blind, placebo-controlled study was conducted to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of subcutaneous administration of BW-00112 in Chinese subjects
Latest Information Update: 02 Dec 2025
At a glance
- Drugs BW 00112 (Primary)
- Indications Dyslipidaemias
- Focus Adverse reactions
Most Recent Events
- 02 Dec 2025 New trial record